Conflicting interpretations and FDA reputation: the case of post-market surveillance of breast implants.

Abstract

Conflicting interpretations regarding the severity of the adverse effects associated with FDA-approved drugs and therapies are common among the United States Food and Drug Administration (FDA), the medical community, patients, and the general public. However, scholars have paid little attention to how these conflicting interpretations may affect the FDA's reputation for facilitating inclusive dialogue between competing policy actors. Focusing on breast implants, a medical device characterized by